Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492800 · ClinicalTrials.gov registry record · NA
Hair Loss Prevention Study for Pancreatic Cancer
A NA study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT04492800: Completed NA study, sponsored by HonorHealth Research Institute.
NCT04492800 is a NA study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04492800, a NA study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
Primary Outcome
Hair preservation was graded and defined based on severity of hair loss (alopecia) Grade 0 or 1 (lower grade) versus Grade 2 (higher grade) as defined by the CTCAE Version 5.0. Grade 0 to 1 is defined as Hair loss of \<50% of normal for that individual that is not obvious from a distance but only on close inspection; Grade 2 or higher is Hair loss of \>=50% normal for that individual that is readily apparent to others.
Interventions
- DEVICE Paxman Scalp Cooling Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT04492800 record still lists
NCT04492800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Paxman Scalp Cooling Device is the first listed.
NCT04492800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04492800 about?
NCT04492800 is a clinical study titled "Hair Loss Prevention Study for Pancreatic Cancer". Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
What is the current status of trial NCT04492800?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2019-12-13. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04492800?
The interventions under investigation include: Paxman Scalp Cooling Device (DEVICE).
Who is sponsoring clinical trial NCT04492800?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04492800's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI